Clinical and surgical management of pheochromocytomas and paragangliomas

Article Sidebar

PDF (Spanish)
Published: 2015-09-30
DOI: https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v35i3.710
Keywords:
pheochromocytoma, paraganglioma, neuroendocrina tumors, hypertension, incidentaloma, catecholamines, metanephrines, adrenalectomy, malignancy, genetics

Main Article Content

Valeria de Miguel
Servicio de Endocrinología, Metabolismo y Medicina Nuclear. Hospital Italiano de Buenos Aires
Paula Cuffaro
Sección Hipertensión Arterial, Servicio de Clínica Médica. Hospital Italiano de Buenos Aires
Juan Medici
Sección de Esófago, Estómago y Duodeno, Servicio de Cirugía General. Hospital Italiano de Buenos Aires
Demetrio Cavadas
Sección de Esófago, Estómago y Duodeno, Servicio de Cirugía General. Hospital Italiano de Buenos Aires

Abstract

Pheochromocytomas and paragangliomas are rare neuroendocrine tumors with different clinical manifestation associated with high morbidity and mortality. Recognize signs and symptoms is the first step in diagnosis. Urinary fractionated metanephrines have an excellent specificity and sensitivity. Computed Tomography (CT) is the first-choice imaging modality for location. F18-DG positron tomography (PET)/CT scanning is the functional modality of choice for metastatic disease. Surgery is the only curative treatment. Minimally invasive adrenalectomy is the surgical approach for most adrenal pheochromocytomas. Perioperative alpha and beta blockade for 7 to 14 days normalize blood pressure and prevent perioperative cardiovascular complications. Is recognize that at least one-third of the patients have disease-causing germline mutations. Genetic testing must be orientated to syndromic features, presentation, localization and biochemical profile of these tumors. Multidisciplinary teams at centers with appropriate expertise are recommended to ensure a favorable outcome

Downloads

Download data is not yet available.

Article Details

Issue

Vol. 35 No. 3 (2015): Revista del Hospital Italiano de Buenos Aires

Section

Review
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

1.
de Miguel V, Cuffaro P, Medici J, Cavadas D. Clinical and surgical management of pheochromocytomas and paragangliomas. Rev Hosp Ital B.Aires [Internet]. 2015 Sep. 30 [cited 2026 Apr. 27];35(3):76-85. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/710

References

Pacak K, JDR. Pheochromocytoma and Paraganglioma [Internet]. Available from: http://www.endotext.org/chapter/pheochromocytoma

Kirmani S, Young WF. Hereditary Paraganglioma-Pheochromocytoma Syndromes. Seattle: University of Washington; 2014.

van Berkel A, Lenders JW, Timmers HJ. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol. 2014;170(3):R109-19. DOI: https://doi.org/10.1530/EJE-13-0882

Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000;85(2):637-44. DOI: https://doi.org/10.1210/jc.85.2.637

Mannelli M, Lenders JW, Pacak K, et al. Subclinical phaeochromocytoma. Best Pract Res Clin Endocrinol Metab. 2012;26(4):507-15. DOI: https://doi.org/10.1016/j.beem.2011.10.008

Motta-Ramirez GA, Remer EM, Herts BR, et al. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol. 2005;185(3):684-8. DOI: https://doi.org/10.2214/ajr.185.3.01850684

Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-42. DOI: https://doi.org/10.1210/jc.2014-1498

Fuxe K, Manger P, Genedani S, et al. The nigrostriatal DA pathway and Parkinson’s disease. J Neural Transm Suppl. 2006;(70):71-83. DOI: https://doi.org/10.1007/978-3-211-45295-0_13

Pacak K, Lenders JWM, Eisenhofer G. Pheochromocytoma Diagnosis, Localization, and Treatment. Malden, MA: Blackwell Publishing; 2007. (http://www.wiley.com/WileyCDA/Wiley Title/productCd-1405149507.html ) DOI: https://doi.org/10.1002/9780470692196

Young WF, NM K. Clinical presentation and diagnosis of pheochromocytoma. UpToDate. 2015. http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-pheochromocytoma

Baid SK, Lai EW, Wesley RA, et al. Brief communication: radiographic contrast infusion and catecholamine release in patients with pheochromocytoma. Ann Intern Med. 2009;150(1):27-32. Erratum in: Ann Intern Med. 2009 Feb 17;150(4):292. DOI: https://doi.org/10.7326/0003-4819-150-1-200901060-00006

Taïeb D, Varoquaux A, Chen CC, et al. Current and future trends in the anatomical and functional imaging of head and neck paragangliomas. Semin Nucl Med. 2013;43(6):462-73. DOI: https://doi.org/10.1053/j.semnuclmed.2013.06.005

Castinetti F, Kroiss A, Kumar R, et al. 15 YEARS OF PARAGANGLIOMA: Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2015;22(4):T135-45 DOI: https://doi.org/10.1530/ERC-15-0175

Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92(11):4069-79. DOI: https://doi.org/10.1210/jc.2007-1720

Prejbisz A, Lenders JW, Eisenhofer G, et al. Cardiovascular manifestations of phaeochromocytoma. J Hypertens. 2011;29(11):2049-60. DOI: https://doi.org/10.1097/HJH.0b013e32834a4ce9

Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am. 2011;40(2):295-311, vii. DOI: https://doi.org/10.1016/j.ecl.2011.02.002

Lebuffe G, Dosseh ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia. 2005;60(5):439-44 DOI: https://doi.org/10.1111/j.1365-2044.2005.04156.x